Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
$10.08
-1.9%
$9.65
$7.78
▼
$12.06
$1.03BN/A187,823 shs243,458 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$13.66
-8.1%
$11.16
$1.39
▼
$24.89
$1.52B2.737.65 million shs15.36 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
-1.95%-5.53%+11.88%+1,007,999,900.00%+1,007,999,900.00%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-8.08%+73.79%+12.52%-11.64%+798.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
$10.08
-1.9%
$9.65
$7.78
▼
$12.06
$1.03BN/A187,823 shs243,458 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$13.66
-8.1%
$11.16
$1.39
▼
$24.89
$1.52B2.737.65 million shs15.36 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
-1.95%-5.53%+11.88%+1,007,999,900.00%+1,007,999,900.00%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-8.08%+73.79%+12.52%-11.64%+798.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
2.89
Moderate Buy$14.9848.61% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
2.33
Hold$10.00-26.79% Downside

Current Analyst Ratings Breakdown

Latest OIG, ESCT, SLS, and TRG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Reiterated RatingMarket Perform
10/20/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
UpgradeStrong-Buy
10/15/2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
Reiterated RatingSell (D-)
10/14/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
UpgradeHold
10/13/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Initiated CoverageMarket Perform
10/13/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Initiated CoverageBuy$13.00
10/13/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Initiated CoverageMarket Outperform
10/13/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Initiated CoverageOutperform$15.00
10/13/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Initiated CoverageBuy$14.00
10/13/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Initiated CoverageBuy$14.00
10/13/2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
Initiated CoverageModerate Buy$15.00
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
N/AN/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/A$0.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
N/AN/AN/A14.00N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$26.86M-$0.20N/AN/AN/AN/A-31.95%-29.86%N/A

Latest OIG, ESCT, SLS, and TRG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.05-$0.05N/A-$0.05N/AN/A
11/10/2026Q3 2026
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
$0.09$0.14+$0.05$0.14$43.71 million$53.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
N/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
14.92
14.92

Institutional Ownership

CompanyInstitutional Ownership
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
2.58%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Orion180 Insurance Group Inc. stock logo
OIG
Orion180 Insurance Group
30099.03 million96.48 millionN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
13203.86 million201.21 millionOptionable

Recent News About These Companies

SELLAS prices $150M public offering at $13 per share
Sellas Life Sciences Shares Sink After Pricing Public Offering
SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Orion180 Insurance Group stock logo

Orion180 Insurance Group NASDAQ:OIG

$10.08 -0.20 (-1.95%)
As of 11/20/2026 04:00 PM Eastern

Orion180 Insurance Group Inc. is a provider of flexible, customer-centric homeowners and flood insurance solutions. Orion180 Insurance Group Inc. is headquartered in Melbourne, Florid.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$13.66 -1.20 (-8.08%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$14.27 +0.61 (+4.47%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.